Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 2, 2024
Daily News
April 2, 2024
- With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
- Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
- Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
- Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
- Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
- Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
- MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
- Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
- Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
- Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…